Biopharmaceutical company Disc Medicine Inc. (IRON) is advancing multiple clinical-stage programs aimed at modifying red blood cell biology, with recent regulatory filings and trial updates placing the company in focus.
The stock closed Tuesday's trading session at $66.08, up 1.57%, with after-hours movement slightly lower at $65.95. Volume reached 370,074 shares, above its average volume of 341,241, reflecting increased activity ahead of several anticipated milestones.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com